Lawitz and colleagues: sofosbuvir regimens for previously untreated hepatitis C

What changed

Sofosbuvir-based treatment gained pivotal genotype-specific clinical evidence.

Scientific scope

Exact 24-author 2013 article and two trials; later interferon-free combinations/approval/elimination separate.

Evidence

The linked sources identify this contribution and its scope. WRS has not independently reconstructed the scientific claims. The record is the exact 2013 NEJM article and its two open-label trials, regimens and populations. HCV discovery, sofosbuvir chemistry, later interferon-free combinations, approvals, elimination programmes and all HCV genotypes remain separate.

Contributors

• The named authors listed in the linked research record · SCIENCE: Complete source byline retained in the research record; this collective display does not merge person identities or measure labor shares.

• Lawitz et al., Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
• Crossref record for sofosbuvir in untreated HCV

Provisional WRS assessment, edition 2026-10-16.1. Independent expert calibration is pending. This grade does not certify correctness or assign ownership.

Full scientific record · Browse contribution grades · Request a correction